本報告已在2011年07月19日停止出版。
免疫學與疫苗學的進步，讓醫界對癌症、免疫性障礙、過敏、自我免疫疾病、海洛因與尼古丁中毒等疫苗研發標的投注殷切的期待。目前全球有千種以上的疫苗在研發中，相對於現有藥物來說很有可能成為成本效率較高的替代品。特別是印度、中國、巴西挾著新銳的設備與豐富的資源，可望在新疫苗的研發上扮演重要的角色。
專門分析多種尖端產業的美國市調公司 Technical Insights, Inc. (總公司：紐約) ，調查分析了新疫苗與療法相關研發技術與動向後，出版了一本綜合報告書 "Emerging Vaccines and Therapies--Analysis of Technological Trends"。
報告書內容包括：目前研發中的各種新疫苗產品、技術與投藥系統定義與分析、研發進展、產品研發、影響疫苗研發的規範等等，內容綱要摘記如下：
1. 摘要
2. 新疫苗技術
- DNA 疫苗
- 序論
- DNA 疫苗用 Polymer Microspheres
- DNA 基礎之 HIV 疫苗臨床實驗
- 透過 Nanorods 傳遞基因材質
- 單株抗體
- 消化器官癌症治療用單株抗體
- HGS 單株抗體的抗 HIV 侵入
- 新式 Vector System
- HIV 用 Adenoviral Vector
- Liposomal 的基因傳遞機制
- 輔助療法
- 促進黏膜免疫反應之 Hybridon 製劑
- 奈米科技基礎的疫苗輔助療法
- 植物基礎疫苗
- 俄國研發初期階段之 HIV 用植物基礎疫苗
- LSBC 研發之植物基礎 HIV 與 HPV 用疫苗
3. 新疫苗投藥途徑
4. 新疫苗產品
5. 新疫苗研發：技術評估
6. 主要聯絡處與主要專利
7. Frost & Sullivan 2005 Science and Technology Awards
8. 參考資料
- 生技相關支出
- 生物製劑相關專利數
- HIV 罹患率與死亡率
- 癌症罹患率與死亡率
- 幼兒死亡率與 HIB 預防接種
Abstract
Vaccines Set to Become Fastest Growing Segment in the Pharmaceuticals Industry
Recent advances in immunology and vaccinology have increased the hope that new vaccines will
target other diseases such as cancers, immune system disorders, allergies, autoimmune diseases and
even cocaine and nicotine addictions. A large number of vaccines under development prove to make the
vaccines market an interesting and dynamic one over the next five years. There are currently 1,000
vaccines in research and development (R&D) worldwide, and in the future, they are expected to be
a cost-effective alternative to conventional treatment. The developing countries such as India,
China, and Brazil with their significant innovative scientific capabilities and resources are likely
to play a major role in contributing to the global R&D efforts in developing novel vaccines.
Though most of the technologies are currently in the initial stages of development they are
excitingly close to reality.
This Frost & Sullivan research identifies and analyzes novel and emerging vaccine products,
technologies, and delivery systems currently under development. The study tries to cover advances in
R&D, product development, and regulatory aspects that impact the research into vaccines.
Participants can also identify potential collaborators, stay ahead of the competition, and keep
abreast with critical developments.
DNA Vaccines Show Promising Results in Clinical Trials
A major portion of global research efforts is being directed toward developing DNA vaccines.
While DNA vaccines for humans are still in preclinical development or in the early-stage clinical
trials, they show immense potential for effectively targeting HIV, herpes, malaria, and influenza,
meningitis and various types of cancer. Moreover, DNA vaccines have the ability to stimulate potent
immune responses without the drawbacks of conventional vaccines.
"The greatest advantage is that they are noninfectious and can be used for producing
vaccines against diseases such as HIV, where inoculation with a dead or attenuated virus is too
risky," explains the analyst of this research. "In addition, DNA vaccines are inherently
stable and do not require constant refrigeration." These vaccines are expected to be
particularly popular in developing countries since it is feasible to produce and purify large
amounts using simple and inexpensive procedures.
Opportunities Presented by Advances in Biotechnology and Immunology
Rapid advances in biotechnology and immunology have been a constant driving force behind the
development of vaccines. "While a detailed understanding of immune responses has been applied
to different stages of vaccine development, advances in biotechnology based on genomics, DNA
platforms, and delivery systems offer significant opportunities for developing new vaccines and
expanding the number of target diseases," explains the analyst.
Researchers are looking at proteins from genetically engineered plants to create edible vaccines.
Although its commercial viability is yet to be proven, oral vaccination provides a cost-effective
and convenient alternative to conventional vaccines. Moreover, an oral vaccine not only elicits a
good immune response but it is also likely to eliminate the geographic limitations inherent in most
vaccination programs.
Table of Contents
- 1. Executive Summary
- 1. Introduction
- 1. Introduction to Vaccines
- 2. An Overview of Current Vaccines Industry
- 2. Scope and Methodology
- 1. Scope and Segmentation of the Research Service
- 2. Methodology
- 2. Emerging Vaccine Technologies
- 1. DNA Vaccines
- 1. Introduction
- 2. Polymer Microspheres for DNA Vaccines (USA)
- 3. DNA-Based HIV Vaccine in Human Trials (USA)
- 4. Delivering Genetic Material through Nanorods (USA)
- 2. Monoclonal Antibodies
- 1. Monoclonal for GI Cancers (USA)
- 2. Panel of HGS Monoclonals Block HIV Entry (USA)
- 3. New Vector Systems
- 1. Adenoviral Vector for HIV (Netherlands)
- 2. Liposomal Gene Delivery System (USA)
- 4. Adjuvants
- 1. Hybridons Agents Trigger Mucosal Immune Response (USA)
- 2. Nanotechnology-Based Vaccine Adjuvant (USA)
- 5. Plant-Based Vaccines
- 1. Russian HIV Plant-Based Vaccine in Preliminary Stages of Development (Russia)
- 2. LSBCs Plant-Based HIV and HPV Vaccines in Development (USA)
- 3. Novel Vaccine Delivery Systems
- 1. Inhalation Delivery
- 1. Tiny Polymer Spheres Deliver Vaccines Directly to the Lungs (USA)
- 2. Bi-Directional Nasal Device Delivers Drug on Exhalation (Norway)
- 3. Dry Powder Inhalers for Consistent and Inexpensive Pulmonary Drug Delivery (USA)
- 4. Simplifying Nasal Route Vaccine Delivery (Denmark)
- 2. Needle-Free Injections
- 1. Aradigms Intraject in Final Stages of Development (USA)
- 2. DNA Influenza Vaccine with Novel Delivery Technology (UK)
- 3. Liquid Jet Injection (USA)
- 3. Transdermal Delivery
- 1. Transcutaneous Immunization (USA)
- 2. Ultrasonic Energy for Skin Permeation (USA)
- 4. Oral Delivery
- 1. New Oral Anthrax Vaccine in the Development Stage (UK)
- 2. Development of a New Oral Vaccine against Diphtheria (Sweden)
- 3. Prospective Oral Vaccine for Cervical Cancer (China)
- 4. Emerging Vaccine Products
- 1. HIV/AIDS Vaccines
- 1. HIV Vaccine with Therapore Technology in Phase I Trials (USA)
- 2. BioVex Dendritic Cell Technology for AIDS Vaccine (UK)
- 3. Transfection Technology for Mercks HIV Vaccine (USA)
- 2. Cancer Vaccines
- 1. P53 Gene Therapeutic Cancer Vaccine (USA)
- 2. Novel Cancer Vaccine in Phase II Trials (UK)
- 3. Mologens Autologous Cancer Vaccine Looks Good in Clinical Trials (Germany)
- 4. Biomira Lung Cancer Vaccine Increases Survival (Canada)
- 5. Novel Approach against Precancerous Cervical Lesions (France)
- 6. Therion: Anti-Cancer Vaccines Use Multiple Antigen Genes (USA)
- 7. GVAX Prostate Cancer Vaccine in Phase III Trials (USA)
- 8. Genzyme: Vaccine Uses Fused Tumor and Dendritic Cells (USA)
- 3. Infectious Disease Vaccines
- 1. GSKs Malaria Vaccine for African Children (USA)
- 2. TIGR Sequence for Pneumococcus (USA)
- 3. Chiron Meningococcal B Vaccine for New Zealand (USA)
- 5. Development of New Vaccines--Technology Assesment
- 1. Trend Analysis
- 1. Technology Trends
- 2. Corporate Collaborations (Part I)
- 3. Corporate Collaborations (Part II)
- 2. Novel Vaccine Technologies - Drivers and Challenges
- 6. Key Contacts and Noteworthy Patents
- 1. Key Contacts
- 1. Industry Contacts
- 2. University Contacts
- 2. Important Patents
- 1. Patents (Companies)
- 2. Patents (Universities)
- 7. Frost & Sullivan 2005 Science and Technology Awards
- 1. Technology Innovation Award
- 1. Award Description
- 2. Award Recipient
- 2. Excellence in Technology
- 1. Award Description
- 2. Award Recipient
- 3. Excellence in Research
- 1. Award Description
- 2. Award Recipient
- 8. Critical Reference Tables
- 1. Biotech Expenditure
- 1. Number of Biotech Companies (1999-2006)
- 2. Government Investment in Biotech R&D (1999-2006)
- 3. Private Investment in Biotech (1999-2006)
- 2. Number of Biotech Patents
- 1. USPTO Biotech Patents (1996-2000)
- 2. EPO Biotech Patents (1996-2000)
- 3. HIV Incidence and Mortality
- 1. HIV Prevalence (1999-2006)
- 2. AIDS Mortality (1999-2006)
- 4. Cancer Incidence and Mortality
- 1. Lung Cancer Incidence (1999-2006)
- 2. Lung Cancer Mortality (1999-2006)
- 3. Prostate Cancer Incidence (1999-2006)
- 4. Prostate Cancer Mortality (1999-2006)
- 5. Infant Mortality and HIB Immunization
- 1. Infant Mortality Rate (1999-2006)
- 2. HIB Immunization (1999-2006)
